Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q6IEG0
UPID:
SNR48_HUMAN
Alternative names:
-
Alternative UPACC:
Q6IEG0; A8K8P4; Q14C91; Q5T339; Q5THM1; Q5THM2; Q96MK1
Background:
The U11/U12 small nuclear ribonucleoprotein 48 kDa protein, with UniProt accession Q6IEG0, plays a crucial role in the splicing mechanism of pre-mRNA, specifically in U12-type 5' splice site recognition. This process is vital for the accurate removal of introns from pre-mRNA, ensuring the correct assembly of mature mRNA molecules for protein synthesis.
Therapeutic significance:
Understanding the role of U11/U12 small nuclear ribonucleoprotein 48 kDa protein could open doors to potential therapeutic strategies. Its involvement in the fundamental process of spliceosome-mediated splicing highlights its potential as a target for modulating gene expression in various diseases.